Media Summary: Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, discusses the results of the Phase II Bob Li, MD, PhD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of the Phase II Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO ...
Kras Mutant Nsclc Codebreak 100 - Detailed Analysis & Overview
Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, discusses the results of the Phase II Bob Li, MD, PhD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of the Phase II Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO ... "Dr Alex Spira speaks to ecancer about the patient-reported outcomes (PRO) from the phase 2 Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, summarizes ongoing clinical trials of ... Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, discusses management options for patients ...
Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, comments on updates in the management of ... Sotorasib is an investigational inhibitor of Outcomes in patients with heavily pre-treated advanced non-small cell Immunotherapy remains the preferred front-line therapy for Last month, the FDA granted accelerated approval of sotorasib (Lumakras) for the treatment of adults with
